Table S1. SCLD group vs. RT group clinicopathological characteristics.
| Characteristics | SCLD (n=146) | RT (n=159) | P value |
|---|---|---|---|
| Age (years) | |||
| <35 | 11 | 11 | |
| ≥35 | 135 | 148 | 0.835 |
| Tumor location | |||
| Left | 87 | 93 | |
| Right | 59 | 66 | 0.846 |
| Tumor quadrant | |||
| Outer upper | 92 | 94 | |
| Outer lower | 12 | 15 | |
| Inner upper | 13 | 15 | |
| Inner lower | 6 | 11 | |
| central | 23 | 24 | 0.838 |
| Primary tumor size | |||
| T1 | 20 | 36 | |
| T2 | 94 | 101 | |
| T3 | 17 | 12 | |
| T4 | 15 | 8 | 0.067 |
| Histological type | |||
| Invasive ductal carcinoma | 121 | 130 | |
| Other types | 25 | 29 | 0.799 |
| ER | |||
| Negative | 59 | 48 | |
| Positive | 87 | 111 | 0.062 |
| PR | |||
| Negative | 77 | 62 | |
| Positive | 69 | 97 | 0.016 |
| HER-2 | |||
| Negative | 110 | 113 | |
| Positive | 36 | 46 | 0.337 |
| Molecular subtype | |||
| Luminal A | 19 | 61 | |
| Luminal B | 71 | 50 | |
| HER-2 overexpressing | 21 | 19 | |
| TNBC | 35 | 29 | <0.001 |
| Ki67 | |||
| ≤14% | 31 | 51 | |
| >14% | 115 | 108 | 0.033 |
| The number of involved axillary lymph nodes | |||
| 0 | 36 | 71 | |
| 1-3 | 31 | 41 | |
| 4-9 | 35 | 30 | |
| ≥10 | 44 | 17 | <0.001 |
| Involvement of infraclavicular lymph node | |||
| No | 110 | 141 | |
| Yes | 36 | 18 | 0.002 |
| NAC | |||
| PD + SD | 50 | 69 | |
| PR + CR | 96 | 90 | 0.089 |
SCLD, supraclavicular lymph node dissection; RT, radiotherapy; ER, estrogen receptor; PR, progestational hormone; HER-2, human epidermal growth factor receptor-2; TNBC, triple negative breast cancer; NAC, neoadjuvant chemotherapy; PD, progressive disease; SD, stable disease; PR, partial disease; CR, complete disease.